An Open-Label, Single-Arm, Phase 2 Study of Extended Carfilzomib Therapy in Subjects Previously Enrolled in Carfilzomib Treatment Protocols
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2017
At a glance
- Drugs Carfilzomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen; Onyx Pharmaceuticals
- 16 Jun 2017 Status changed from active, no longer recruiting to completed.
- 14 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 May 2017.
- 14 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 May 2017.